EUROPE COMPANION DIAGNOSTICS MARKET 2022-2028

Triton’s report states that the companion diagnostics market in Europe is anticipated to develop at a compound annual growth rate of 12.61% during the forecast period 2022-2028.

Report scope can be customized per your requirements. Request For Customization

The countries studied in the region comprise:

• The United Kingdom

• Germany

• France

• Spain

• Italy

• Poland

• Rest of Europe

In Europe, Germany secures major shares in the companion diagnostics market. The growing focus on R&D activities to advance precision medicine technologies is anticipated to fuel the market’s scope in the region. Moreover, the high demand for technologically advanced medical diagnostics and the establishment of various laboratories elevates the demand for companion diagnostics tests. Countries such as Germany, France, and the UK are estimated to showcase significant growth, owing to the presence of prominent players, developed healthcare, and technological innovation. Therefore, as mentioned above, these factors are projected to drive the market’s growth.

Germany, for instance, has witnessed a substantial rise in the demand to reduce expenses on targeted treatment. This resulted in the authorization of a new law that imposed a time limit to evaluate innovative diagnostic tests, including CDx. Moreover, this helped address multiple restraints faced by the German market. Along with this, the rising focus on precision medicine creates novel opportunities for the companion diagnostics market.

On the other hand, unlike in other nations, the CDx evaluation process is integrated with technology appraisal in the United Kingdom. This avoids delay in the decision-making process. The government has also set up an assessment program for CDx tests. Along with this, several companies are promoting innovative and cost-effective solutions, boosting the development of the companion diagnostics market.

Pharmaceutical and biopharmaceutical companies employ companion diagnostics kits to select suitable candidates for clinical trials. The rising pharmaceutical R&D spending and application of companion diagnostics in drug development have majorly driven the industry’s growth. The market is assessed based on consumer, indicator, commodity, and mechanism. The consumer segment is branched into pharmaceutical and biopharmaceutical companies, reference laboratories, and other consumers.

The notable companies in the market include GE Healthcare, Illumina Inc, Myriad Genetics, Roche Diagnostics, Sysmex Corporation, and Genomic Health.

GE Healthcare is a business segment of General Electric. It is among the leading companies offering medical technologies and related services. The company’s product line includes medical diagnostics, patient monitoring systems, drug discovery technologies, and performance solution services, among others. It also provides products for biopharmaceutical manufacturing, imaging agents, healthcare IT, and cellular technologies. GE Healthcare operates across multiple regions, including Europe.

Key deliverables of the report:

● Market CAGR during the forecasting years 2022-2028

● Detailed data highlighting key insights, industry components, and market strategies

● Comprehensive information and estimation of the companion diagnostics market revenue growth in Europe and its influence on the parent market

● In-depth study of forthcoming trends in consumer behavioral patterns

● A meticulous analysis of the competitive landscape, vendor scorecard, and Porter’s Five Forces

● A wide-ranging study of factors that will challenge the Europe companion diagnostics market’s growth during the upcoming years

Want to get specific insights? Our team of analysts can customize this report based on your preferences. Connect with us here.

Major Players in the Market

Related Reports

Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT

Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT

Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT

Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT

Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT

Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Lifesciences

ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028

Market by Therapeutics, Diagno ..

VIEW REPORT

Lifesciences

ASIA-PACIFIC AMNIOTIC MEMBRANE MARKET 2022-2028

Market by Type, Application, E ..

VIEW REPORT

Table of Content

1. EUROPE COMPANION DIAGNOSTICS MARKET - SUMMARY

2. INDUSTRY OUTLOOK

2.1. IMPACT OF COVID-19 ON THE COMPANION DIAGNOSTICS MARKET

2.2. KEY INSIGHTS

2.2.1. COMMERCIAL SUCCESS OF PRECISION MEDICINE TREATMENT

2.2.2. ADOPTION OF PREDICTIVE BIOMARKERS

2.2.3. FUSION OF COMPUTER SCIENCE AND BIOLOGY

2.3. PORTER’S FIVE FORCES ANALYSIS

2.3.1. THREAT OF NEW ENTRANTS

2.3.2. THREAT OF SUBSTITUTES

2.3.3. BARGAINING POWER OF BUYERS

2.3.4. BARGAINING POWER OF SUPPLIERS

2.3.5. THREAT OF COMPETITIVE RIVALRY

2.4. KEY BUYING IMPACT ANALYSIS

2.4.1. COST

2.4.2. AVAILABILITY

2.4.3. SENSITIVITY & SPECIFICITY

2.4.4. EFFICACY

2.5. MARKET ATTRACTIVENESS INDEX

2.6. VENDOR SCORECARD

2.7. INDUSTRY COMPONENTS

2.8. REGULATORY FRAMEWORK

2.9. KEY MARKET STRATEGIES

2.9.1. ACQUISITIONS

2.9.2. PRODUCT LAUNCHES

2.9.3. CONTRACTS & AGREEMENTS

2.10. MARKET DRIVERS

2.10.1. INCREASE IN INCIDENCE OF MEDICATION REACTIONS

2.10.2. INCREASING PREVALENCE OF CANCER CASES AND FATALITIES

2.10.3. RISING PREVALENCE OF PRECISION MEDICINES

2.11. MARKET CHALLENGES

2.11.1. WEAK REIMBURSEMENT FRAMEWORK

2.11.2. COMMON CASES OF LEAKAGE IN ONCOLOGY COMPANION DIAGNOSTICS

2.12. MARKET OPPORTUNITY

2.12.1. ONGOING RESEARCH AND INVESTMENTS IN NEXT GENERATION GENE-SEQUENCING

3. EUROPE COMPANION DIAGNOSTICS MARKET OUTLOOK - BY MECHANISM

3.1. IN-SITU HYBRIDIZATION

3.2. POLYMERASE CHAIN REACTION

3.3. IMMUNOHISTOCHEMISTRY

3.4. NEXT GENERATION SEQUENCING

3.5. OTHER MECHANISMS

4. EUROPE COMPANION DIAGNOSTICS MARKET OUTLOOK - BY INDICATOR

4.1. ONCOLOGY

4.2. NEUROLOGY

4.3. INFECTIOUS DISEASES

4.4. OTHER INDICATORS

5. EUROPE COMPANION DIAGNOSTICS MARKET OUTLOOK - BY CONSUMER

5.1. PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES

5.2. REFERENCE LABORATORIES

5.3. OTHER CONSUMERS

6. EUROPE COMPANION DIAGNOSTICS MARKET OUTLOOK - BY COMMODITY

6.1. ASSAY KITS AND REAGENTS

6.2. SOFTWARE AND SERVICES

7. EUROPE COMPANION DIAGNOSTICS MARKET - COUNTRY OUTLOOK

7.1. UNITED KINGDOM

7.2. GERMANY

7.3. FRANCE

7.4. SPAIN

7.5. ITALY

7.6. POLAND

7.7. REST OF EUROPE

8. COMPETITIVE LANDSCAPE

8.1. ABBOTT LABORATORIES

8.2. ALMAC GROUP

8.3. ARUP LABORATORIES

8.4. BIOCARTIS

8.5. BIOMERIEUX

8.6. DANAHER CORPORATION

8.7. GE HEALTHCARE

8.8. GENOMIC HEALTH

8.9. ILLUMINA INC

8.10. MYRIAD GENETICS

8.11. QIAGEN

8.12. ROCHE DIAGNOSTICS

8.13. SYSMEX CORPORATION

8.14. THERMO FISHER SCIENTIFIC

8.15. AGILENT

9. RESEARCH METHODOLOGY & SCOPE

9.1. RESEARCH SCOPE & DELIVERABLES

9.2. SOURCES OF DATA

9.3. RESEARCH METHODOLOGY

List of Tables

TABLE 1: EUROPE COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 2: VENDOR SCORECARD

TABLE 3: LIST OF ACQUISITIONS

TABLE 4: LIST OF PRODUCT LAUNCHES

TABLE 5: LIST OF CONTRACTS & AGREEMENTS

TABLE 6: NUMBER OF CANCER PATIENTS IN 2020

TABLE 7: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)

TABLE 8: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)

TABLE 9: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)

TABLE 10: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)

TABLE 11: EUROPE COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

List of Figures

FIGURE 1: MARKET ATTRACTIVENESS INDEX

FIGURE 2: INDUSTRY COMPONENTS

FIGURE 3: FDA FRAMEWORK

FIGURE 4: CDX LEAKAGE POINTS

FIGURE 5: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2021 & 2028 (IN %)

FIGURE 6: EUROPE COMPANION DIAGNOSTICS MARKET, BY IN-SITU HYBRIDIZATION, 2022-2028 (IN $ MILLION)

FIGURE 7: EUROPE COMPANION DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2022-2028 (IN $ MILLION)

FIGURE 8: EUROPE COMPANION DIAGNOSTICS MARKET, BY IMMUNOHOSTOCHEMISTRY, 2022-2028 (IN $ MILLION)

FIGURE 9: EUROPE COMPANION DIAGNOSTICS MARKET, BY NEXT GENERATION SEQUENCING, 2022-2028 (IN $ MILLION)

FIGURE 10: EUROPE COMPANION DIAGNOSTICS MARKET, BY OTHER MECHANISMS, 2022-2028 (IN $ MILLION)

FIGURE 11: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2021 & 2028 (IN %)

FIGURE 12: EUROPE COMPANION DIAGNOSTICS MARKET, BY ONCOLOGY, 2022-2028 (IN $ MILLION)

FIGURE 13: EUROPE COMPANION DIAGNOSTICS MARKET, BY NEUROLOGY, 2022-2028 (IN $ MILLION)

FIGURE 14: EUROPE COMPANION DIAGNOSTICS MARKET, BY INFECTIOUS DISEASES, 2022-2028 (IN $ MILLION)

FIGURE 15: EUROPE COMPANION DIAGNOSTICS MARKET, BY OTHER INDICATORS, 2022-2028 (IN $ MILLION)

FIGURE 16: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2021 & 2028 (IN %)

FIGURE 17: EUROPE COMPANION DIAGNOSTICS MARKET, BY PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, 2022-2028 (IN $ MILLION)

FIGURE 18: EUROPE COMPANION DIAGNOSTICS MARKET, BY REFERENCE LABORATORIES, 2022-2028 (IN $ MILLION)

FIGURE 19: EUROPE COMPANION DIAGNOSTICS MARKET, BY OTHER CONSUMERS, 2022-2028 (IN $ MILLION)

FIGURE 20: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2021 & 2028 (IN %)

FIGURE 21: EUROPE COMPANION DIAGNOSTICS MARKET, BY ASSAY KITS AND REAGENTS, 2022-2028 (IN $ MILLION)

FIGURE 22: EUROPE COMPANION DIAGNOSTICS MARKET, BY SOFTWARE AND SERVICES, 2022-2028 (IN $ MILLION)

FIGURE 23: EUROPE COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)

FIGURE 24: UNITED KINGDOM COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 25: GERMANY COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 26: FRANCE COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 27: SPAIN COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 28: ITALY COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 29: POLAND COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 30: REST OF EUROPE COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)